Oncotarget

Research Papers:

Prognostic value of long non-coding RNA TUG1 in various tumors

Na Li, Ke Shi, Xinmei Kang and Wei Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:65659-65667. https://doi.org/10.18632/oncotarget.20025

Metrics: PDF 1498 views  |   HTML 1891 views  |   ?  


Abstract

Na Li1, Ke Shi2, Xinmei Kang2 and Wei Li2

1Department of Pathology, The First Affiliated Hospital of Hunan University of Medicine, Huaihua, Hunan Province, People’s Republic of China

2Department of Geriatrics, Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, Hunan Province, People’s Republic of China

Correspondence to:

Wei Li, email: [email protected]

Keywords: TUG1, cancer, clinical outcome, prognosis

Received: June 22, 2017     Accepted: July 26, 2017     Published: August 07, 2017

ABSTRACT

Taurine up-regulated gene 1 (TUG1) is a long non-coding RNA (lncRNA), has been reported that be dysregulated in various tumors, involved in proliferation and apoptosis in a variety of tumor cells. To detect the clinical significance of TUG1 expression in tumor patients, we carried out current systematic review and meta-analysis investigating its relation with the prognosis and clinicopathological features of cancers. A total of 15 studies comprise 1560 patients were analyzed. The pooled results showed that no significant relationship between high TUG1 expression and overall survival (OS) (HR = 1.28, 95% CI: 0.96–1.69, P = 0.091) in various tumors. In the subgroup analysis by cancer type, elevated TUG1 expression was associated with poorer survival in cancer patients with high TUG1 expression subgroup but better survival in patients with low TUG1 expression subgroup. Over-expression of TUG1 associated with significantly unfavorable survival for bladder cancer (HR=2.67, 95% CI: 1.47–4.87, P = 0.001). Up-regulation of TUG1 correlated with distant metastasis (DM) (OR = 4.22, 95% CI: 2.66–6.70, P < 0.001) and tumor differentiation (OR = 2.45, 95% CI: 1.28–4.70, P = 0.007), but failed to show inline to gender (OR = 1.04, 95% CI: 0.77–1.42, P = 0.774), age (OR = 0.75, 95% CI: 0.51–1.10, P = 0.136), lymph node metastasis (LNM) (OR = 1.45, 95% CI: 0.85–2.50, P = 0.177), and TNM stage (OR = 0.55, 95% CI: 0.17–1.81, P = 0.326). The overall results suggest lncRNA TUG1 may be a useful prognostic biomarker in cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20025